Regulatory single nucleotide polymorphisms (rSNPs) at the promoters 1A and 1B of the human APC gene

Marina Yu Matveeva, Elena V. Kashina, Vasily V. Reshetnikov, Leonid O. Bryzgalov, Elena V. Antontseva, Natalia P. Bondar and Tatiana I. Merkulova

From The International Conference on Bioinformatics of Genome Regulation and Structure\Systems Biology (BGRS\SB-2016)
Novosibirsk, Russia. 29 August-2 September 2016

Abstract
Background: Germline mutations in the coding sequence of the tumour suppressor APC gene give rise to familial adenomatous polyposis (which leads to colorectal cancer) and are associated with many other oncopathologies. The loss of APC function because of deletion of putative promoter 1A or 1B also results in the development of colorectal cancer. Since the regions of promoters 1A and 1B contain many single nucleotide polymorphisms (SNPs), the aim of this study was to perform functional analysis of some of these SNPs by means of an electrophoretic mobility shift assay (EMSA) and a luciferase reporter assay.

Results: First, it was shown that both putative promoters of APC (1A and 1B) drive transcription in an in vitro reporter experiment. From eleven randomly selected SNPs of promoter 1A and four SNPs of promoter 1B, nine and two respectively showed differential patterns of binding of nuclear proteins to oligonucleotide probes corresponding to alternative alleles. The luciferase reporter assay showed that among the six SNPs tested, the rs75612255 C allele and rs113017087 C allele in promoter 1A as well as the rs138386816 T allele and rs115658307 T allele in promoter 1B significantly increased luciferase activity in the human erythromyeloblastoid leukaemia cell line K562. In human colorectal cancer HCT-116 cells, none of the substitutions under study had any effect, with the exception of minor allele G of rs79896135 in promoter 1B. This allele significantly decreased the luciferase reporter activity.

Conclusion: Our results indicate that many SNPs in APC promoters 1A and 1B are functionally relevant and that allele G of rs79896135 may be associated with the predisposition to colorectal cancer.

Keywords: Regulatory SNPs, APC, Promoters, EMSA, Luciferase reporter, Oncopathology

Background
The adenomatous polyposis coli (APC) gene is mapped to chromosome 5q and encodes a protein consisting of 2843 amino acid residues that has been implicated in various cellular functions [1, 2]. In particular, the APC protein is best known as a negative regulator of the transcription factor (TF) β-catenin, an effector of the Wnt signaling pathway [3]. As a component of this signaling pathway, APC participates in a multiprotein ‘destruction complex’ that targets the proto-oncogene β-catenin for ubiquitin-mediated proteolysis [4]. The loss of APC function leads to translocation of β-catenin from the lateral cell membrane to the nucleus, where it promotes transcription of multiple genes involved in tumour growth and invasion [2].

Germline mutations in this tumour suppressor gene (APC) give rise to familial adenomatous polyposis (FAP). The latter is an autosomal-dominant colorectal-cancer predisposition syndrome and accounts for ~1% of newly diagnosed cases of colorectal cancer. FAP is characterised by...
the development of multiple adenomatous polyps (from hundreds to thousands) in the large intestine [5]. The great majority of the mutations observed in the APC gene in patients with FAP are detected in the coding part of the gene. Usually, these are frameshift mutations caused by insertions or deletions of nucleotides and point mutations that predominantly generate a truncated APC peptide. Most of known mutations in APC affect codons 1250–1464 [6, 7].

Many other oncopathologies are also associated with mutations in APC’s coding sequence. For example, in the case of pancreatic acinar cell carcinomas, there is a report of a frameshift mutation characterised by an insertion of 170 nucleotides after nucleotide 4177 and resulting in a truncated protein [8]. Likewise, the molecular basis of Turcot syndrome (colonic polyposis and a primary brain tumour in the same patient) is truncated variants of the APC protein [9]. Moreover, mutations in APC’s coding regions were detected in 23% of cases of ileal enterochromaffin cell neuroendocrine neoplasms; in particular, 57% were missense and 14% were nonsense or frameshift mutations [10]. Mutations in exon 15 of the APC gene were detected in 22.1% of cases of gastric cancer [11].

In addition to mutations in the coding sequence, a loss of APC gene function can occur through alternative genetic and epigenetic mechanisms such as promoter deletion or methylation. At present, there are two known alternative start sites for APC that are located 17 and 47 kb upstream of the initiating methionine codon, respectively; from these start sites, alternative mRNAs containing exon 1A or 1B are transcribed. By default it is believed that these transcripts originate in alternative promoters 1A and 1B [12] although direct evidence for the existence of these promoters has not been obtained yet. It is known that big deletions encompassing any of these start sites cause FAP. Thus, Charames et al. identified a germline deletion corresponding to promoter 1A and 5′ untranslated regions of APC in 28-year-old proband of Canadian Mennonite FAP family. This large deletion results in allele silencing and was also detected among the proband’s other clinically affected siblings while the unaffected ones do not carry the same deletion [13]. Then a deletion (61 kb) encompassing half of promoter 1B was identified in the largest family of the Swedish Polyposis Registry, that leads to an imbalance in allele-specific APC expression. The deletions were detected in all of the affected 11 individuals, but not in the normal controls (50 individuals) [14]. Additionally a novel ~11 kb deletion that encompasses the APC 1B promoter and exon was detected in affected (but not in unaffected) family members of three kindreds from USA FAP registry. This deletion was accompanied by silencing of one of the APC alleles as well [15] Hypermethylation of putative promoter 1A has also been reported for familial polyposis and human colorectal cancer [16, 17].

According to dbSNP NCBI, the regions of promoters 1A and 1B contain a multitude of single nucleotide polymorphisms (SNPs). It is well known that if SNPs that are located in promoter regions of candidate genes change a TF’s binding pattern or the affinity for these proteins and thus influence the level of gene transcription, then they may be promising biomarkers of genetic predisposition to various diseases [18–20]. Nevertheless, SNPs of APC promoters are still poorly studied. Therefore, in the present study, we conducted a functional analysis of some SNPs located in the regions of promoters 1A and 1B; this analysis included assessment of the influence of nucleotide substitutions on binding patterns of nuclear proteins in an electrophoretic mobility shift assay (EMSA) and on activity of these promoters in luciferase reporter experiments.

Methods

Cell lines, nuclear extract preparation and electrophoretic mobility shift assays

The cultivation of cell lines (human hepatoma cells HepG2, human cervical adenocarcinoma cells HelaS3, human erythromyeloblastoid leukemia cells K562, human colorectal cancer cells HCT-116), preparation of nuclear extracts and Electrophoretic Mobility Shift Assays (EMSA) has been described previously [21].

Construction of plasmids containing 1A и 1B APC promoter regions

To construct the target 1A и 1B APC promoter-reporter plasmids, we synthesized the DNA fragments by amplifying the 517-bp 1B promoter region (chr5:112042901–112043417; GRCh37/hg19) and the 435-bp 1A promoter region (chr5:112073194–112073721; GRCh37/hg19) using HCT-116 genomic DNA as a template. The primers were 5′- CTCTCTCGAGTCATCTTCTATCA TCAGCGTCTA −3′ (1BXho forward) and 5′- ACCCAA GCTTATAGGGGCGCCAGGGCC −3′ (1Bhind reverse) CTCTCTCGAGGTGCTGCAAAAATCATAGCA ATCG −3′ (APCXhol forward) and 5′- ACCCAAAGCT TTGTGCAAGGAAAAGCCCATC −3′ (APChindIII reverse) correspondingly. To facilitate plasmid construction, two endonuclease sites, Xhol and HindIII were inserted to both ends of the amplicon (underlined sequences). PCR was performed as follows: 200 μM dNTP; 10-x As-buffer (65 mM Tris-HCl pH 8.9; 1,6 mM (NH4)2SO4; 0.05% Tween 20, 15mM MgCl2); 2,5 pmoles of reverse APChind primer + forward APCXho primer or 2,5 pmoles of forward 1BXho primer + reverse 1BHind primer; 0,25 μg AHK; 1 U Taq - polymerase (SibEnzyme, Russia). The amplified fragment was digested with Xhol and HindIII, and then cloned into the luciferase expression vector pGL4.10[luc2] (Promega) with T4 ligase. The constructs were all confirmed by DNA sequencing.
Site-directed mutagenesis
The 6 pairs of mutagenic oligonucleotide primers used in this study are listed in Table 2, which were designed to amplify the mutant fragments. These primer pairs were overlapped by 2/3 of the length, with mutated bases at the position 8 in the direction of 5’ –> 3’. PCR reaction was performed in a two steps. As a first PCR template the promoter-reporter plasmids pGL4.10 - 1A and pGL4.10 – 1B were used. The first PCR mixture contained 200 μM dNTP; 10-х As-buffer (65 mM Tris-HCl pH 8.9; 1.6 mM (NH4)2SO4; 0.05% Tween 20, 15 mM MgCl2); 2.5 pmole of reverse APCHind or of reverse 1BHind primer or of 2.5 pmole of forward APCHind or 1Bxho primer or of forward 1BXho primer + reverse mutagenic oligonucleotide primer (step 1–2); 0.25 μg ДНК; 1 U Taq - polymerase (SibEnzyme, Russia). As the second –primer or of forward 1BXho primer + reverse mutagenic oligonucleotide primer (step 1–2); 0.25 μg ДНК; 1 U Taq - polymerase (SibEnzyme, Russia). As the second PCR template amplicons from the first PCR reactions were used adds primers. The presence of the mutations was confirmed by Sanger’s sequencing as described [22].

Luciferase reporter assay
For luciferase reporter assays HCT -116 and K562 cells were used. The plasmids under study were co-transfected with pRL-TK using Screen FectA (Incella GmbH, Germany). Luciferase activity was measured 24 h after transfection by using the dual-luciferase reporter assay kit (Promega, USA).

Statistical analysis
STATISTICA 6 was used for statistical analysis.

Results
Both putative 1A и 1B APC promoters drive transcription in the in vitro reporter assay
Previously, we developed a method for whole-genome identification of regulatory regions on the basis of the assumption that enrichment of a genomic region for peaks from high-throughput sequencing of chromatin immunoprecipitation material (ChIP-Seq) indicates that this is a regulatory region [21]. Application of this approach to APC revealed large clusters of ChIP-Seq peaks (up to 28) in two distinct regions (Additional file 1). These regions include start sites for APC’s alternative transcripts containing exon 1A or 1B, which apparently originate in alternative promoter 1A or 1B [12]. To date, there are some data on the expression patterns of the above-mentioned alternative transcripts of APC in various organs and tissues [13, 23], but experiments on direct study of activity of promoters 1A and 1B have not been conducted. To close this gap, we created reporter constructs containing either a distal (1B) (-301; +216; chr5: 112042901–112043417) or proximal (1A) (-315; +120; chr5: 112073194–112073721) APC promoter by cloning of the corresponding fragments into the promoterless plasmid pGL4.10. The results showed that after transfection of the K562 cells with one of these plasmid constructs, expression of the luciferase reporter gene under control of promoter 1A was fourfold stronger than that of the reference promoterless plasmid pGL4.10. After transfection with the plasmid containing promoter 1B, the relative luciferase activity was 22-fold greater than the reference activity (Fig. 1). Therefore, activity of promoter 1B was approximately sixfold higher than that of promoter 1A.

Similar results were obtained with HCT-116 cells although in this case, both promoters showed even higher activity. In particular, under the control of promoter 1A, expression of the luciferase gene increased 10-fold, whereas under control of promoter 1B as much as 80-fold in comparison with the reference plasmid (pGL4.10; Fig. 1). The two constructs differed by the factor of 8, which approximately matches the difference in activity of promoters 1A and 1B in K562 cells.

Overall, this analysis revealed that, when cloned into a promoterless plasmid, the above-mentioned regions of the APC gene indeed behave as a promoters in transfection experiments, and promoter 1B was found to enhance expression of the reporter gene more strongly than promoter 1A did.

Influence of SNPs from promoters 1A and 1B on nuclear proteins binding
According to data from dbSNP NCBI [24] there are many SNPs in promoter regions of APC. For empirical analysis, we randomly selected 15 SNPs (rs75612255, rs79734816, rs77733015, rs78597499, rs35417795, rs113017087, rs75996864, rs115242894, rs80112297, rs76241113, rs80313086, rs115658307, rs138386816, rs7986135, and rs78429131) (Fig. 2). For each of them, double-stranded oligonucleotides (corresponding to alternative alleles) were synthesised (Table 1). These oligonucleotides were then used as DNA probes in EMSA experiments with nuclear extracts from four human cell lines (HepG2, HeLaS3, HCT-116, and K562). We used two to three independent replicates in each EMSA.

The typical example of changes in a binding pattern is shown in Fig. 3. One can see that when nuclear extracts from HeLaS3, HCT-116, and K562 cells were used, allele C (rs75612255) differed from allele T by the absence of the highest retarded band. When HepG2 cell extract was used, this band was not observed for both alleles, apparently as a result of the absence of the corresponding TF in these cells. On the other hand, in the binding assay of proteins from this cell line, a new retarded band appeared, and its intensity was much lower in the case of allele C.

Final results of EMSAs are shown in Table 1. A result was deemed positive (labelled with the + sign) if at least
one cell line showed a change in the binding pattern of nuclear proteins. Such changes were observed for 11 (rs75612255, rs79734816, rs35417795, rs113017087, rs7599864, rs115242894, rs80112297, rs76241113, rs80313086, rs138386816, and rs79896135) of the 15 SNPs tested. This finding suggests that the SNPs in question can destroy (or create) a binding site for some TFs and/or enhance or weaken the binding sites for other TFs, and under appropriate conditions, may influence the regulation of gene expression at the transcriptional level.

For experiments with the luciferase system, we selected two SNPs from each alternative promoter - rs75612255:

![Fig. 1 Analysis of activity of APC promoters in the reporter constructs. The luciferase activity was measured by the dual-luciferase reporter assay kit (Promega, USA). Firefly luciferase activity was normalized to Renilla luciferase activity. The bars indicated the mean ± SE of the luciferase activity (N=7)](image)

![Fig. 2 The scheme of location of the two APC promoter regions (1A and 1B) and the position of the SNPs selected in the present study](image)
### Table 1 List of oligonucleotide probes tested in EMSA

| SNP identifier in dbSNP NCBI database | Sequences of oligonucleotides 5'→3' | Coordinates (hg19) | Minor Allele Count (MAF) | Promoter |
|----------------------------------------|-----------------------------------|-------------------|--------------------------|----------|
| Rs75612255: T > C Allele T: ATTTATTACTCTCCCTCACCTCCGACATC Allele C: ATTTATTACTCTCCCTCACCTCCGACATC | Chr5:112737543 (−316), 5'-flank | NA | 1A |
| Rs79734816: T > C Allele T: TCTGCCCTGGGAGCCACCTCCCGACATC Allele C: TCTGCCCTGGGAGCCACCTCCCGACATC | Chr5:112737587 (−227), 5'-flank | NA | 1A |
| Rs77733015: T > G Allele T: GGCTGAGCTGCTGGGACCCCGCGCATC Allele G: GGCTGAGCTGCTGGGACCCCGCGCATC | Chr5:112737699 (−160), 5'-flank | NA | 1A |
| Rs78597499: T > G Allele T: AGGAGGCGCTGCTGGGACCCCGCGCATC Allele G: AGGAGGCGCTGCTGGGACCCCGCGCATC | Chr5:112737704 (−155), 5'-flank | NA | 1A |
| Rs35417795: 112737713delG Allele del: GTGCGGTTGGGCGGGTCCTGCGCATC Allele G: GTGCGGTTGGGCGGGTCCTGCGCATC | Chr5:112737713 (−146), 5'-flank | NA | 1A |
| Rs113017087: T > C Allele T: GTGTAATCCGCTGGAATTTGGTGCACCGGGCGCTC Allele C: GTGTAATCCGCTGGAATTTGGTGCACCGGGCGCTC | Chr5:112737780 (−79), 5'-flank | C = 0.0032/16 | 1A |
| Rs75996864: T > G Allele T: GTGTAATCCGCTGGAATTTGGTGCACCGGGCGCTC Allele G: GTGTAATCCGCTGGAATTTGGTGCACCGGGCGCTC | Chr5:112737860 (1), 5'-UTR | NA | 1A |
| Rs115242894: G > C Allele G: GTATTGGTGACCGGGCGCTC Allele C: GTATTGGTGACCGGGCGCTC | Chr5:112737874 (15), 5'-UTR | C = 0.0042/21 | 1A |
| Rs80112297: A > G Allele A: GCTTGCTGCGGGGGGGAAGGTGGTTTTCCCTC Allele G: GCTTGCTGCGGGGGGGAAGGTGGTTTTCCCTC | Chr5:112737967 (108), intron | NA | 1A |
| Rs76241113: A > G Allele A: GCCGGGGAAGGGGGGAAGGTGGTTTTCCCTC Allele G: GCCGGGGAAGGGGGGAAGGTGGTTTTCCCTC | Chr5:112737974 (115), intron | NA | 1A |
| Rs80313086: T > G Allele T: GGGGAGGGGGAAAAAGGTGGTTTTCCCTC Allele G: GGGGAGGGGGAAAAAGGTGGTTTTCCCTC | Chr5:112737978 (119), intron | NA | 1A |
| Rs115658307: C > T Allele C: CAAGATGGCGGAGGGCCCTGCACTCGAACGCAAGGGGCGCATC Allele T: CAAGATGGCGGAGGGCCCTGCACTCGAACGCAAGGGGCGCATC | Chr5:112707537 (33), 5'-UTR | T = 0.0054/27 | 1B |
| Rs138886816: C > T Allele C: CGGCGGGTCTGCTGGGGAAGGGGATGCTGGTTTTCCCTC Allele T: CGGCGGGTCTGCTGGGGAAGGGGATGCTGGTTTTCCCTC | Chr5:112707566 (62), 5'-UTR | T = 0.0088/44 | 1B |
| Rs79896135: C > G Allele C: AGCTAGGCTGCTGCGGGGGGCGCTGCACGCAAGGGGCGCATC Allele G: AGCTAGGCTGCTGCGGGGGGCGCTGCACGCAAGGGGCGCATC | Chr5:112707585 (81), 5'-UTR | G = 0.1777/890 | 1B |
| Rs78429131: T > G Allele T: AGGAAGGTGGAAAGCCTCTGCTGGTTTTCCCTC Allele G: AGGAAGGTGGAAAGCCTCTGCTGGTTTTCCCTC | Chr5:112707687 (183), 5'-UTR | G = 0.0767/384 | 1B |

![Fig. 3](image-url) Rs75612255: T > C alters the binding patterns of nuclear proteins from HeLaS3, HepG2, HCT-116, and K562 cells. Changes in the binding of allelic variants with the nuclear proteins are indicated by arrows.
T > C and rs113017087: T > C (from 1A) and rs138
386816: C > T and rs79896135: C > G (from 1B)—that
showed differential patterns of binding of nuclear proteins
to oligonucleotide probes representing the alternative al-
leles. Besides, we analysed two SNPs from promoter 1B
(rs115658307: C > T and rs78429131: T > G) that did not
change the protein binding pattern, because it is known
that substitutions that do not affect the binding of
nuclear-extract proteins can nevertheless influence the ex-
pression of a reporter [22].

Effect of SNPs from promoters 1A and 1B on
transcriptional activity
To evaluate the effects of rs75612255 T > C, rs113017087
T > C, rs138386816: C > T, rs79896135: C > G, rs11565
8307: C > T, and rs78429131: T > G on transcriptional ac-
tivity, we prepared a series of reporter plasmids containing
the corresponding substitutions in promoter 1A or 1B
(Table 2). For transfection experiments, we used the hu-
man colorectal cancer HCT-116 cells and the human ery-
thromyeloblastoid leukaemia cell line K562.

According to the data in Fig. 4, the majority of SNPs
under study were functionally active in a luciferase re-
porter assay, however pointing the obvious cell-specific
effects. In K562 cells, the rs75612255 C allele and
rs113017087 C allele of promoter 1A as well as alleles
rs138386816 T and rs115658307 T of promoter 1B sig-
ificantly increased luciferase activity, whereas in HCT-
116 cells, there was no difference in the activity of the
promoters containing alternative alleles at these posi-
tions. In contrast, minor allele G of rs79896135 from
promoter 1B, which has no effect on the reporter gene
expression in K562 cells, significantly decreased the lu-
ciferase activity in HCT-116 cells. Among these five
SNPs, four (rs75612255, rs113017087, rs138386816, and
rs79896135) also yielded differential binding patterns of
nuclear proteins in EMSAs. Rs115658307 manifested a
functional activity only in a luciferase reporter assay.

This may be because the transfection experiments were
performed on live cells, whereas EMSA was an in vitro
(cell-free) method. Preparation of nuclear extracts for an
EMSA is time-consuming, and some nuclear proteins
may lose activity by the end of this procedure. Accord-
ingly, the reporter assays may be more informative.
Rs78429131 was found to have no effect in both assays
of functional activity.

Table 2 Primers for site-directed mutagenesis

| SNP             | Mutagenic oligonucleotide primer 5’→3’ | Forward | Reverse |
|-----------------|----------------------------------------|---------|---------|
| rs115658307: C > T | Forward:GGAGGGTAAAGTACGGAAGGCGGGG | GCTACTTACCCCTCCGGACCTTTG | GGGG |
| rs138386816: C > T | Forward:GGCGGCGCTGAAAGCTGACGCGCTCGT | GCTTACCGGGCGCCAGACCCCGCC | GCGG |
| rs79896135: C > G | Forward:GGCCTGCGGGGAGGTGCAGGGGCGGG | GCCCTACCCGGCCAGCCTTTG | TCCC |
| rs78429131: T > G | Forward:GACGACCTAGTCCCTCCGCGG | CAACGACCGGCGCGCTGGGT | TCTT |
| rs75612255: T > C | Forward:CTTTCACCCCTCCCGG | AGTGGGAGTAGAATAAATTA | TTCG |
| rs113017087: T > C | Forward:GCTTGACGCGGACGGCGGCTTTC | CAGGAGGTGGG | GCGG |

Note: The points of site-direct mutagenesis is marked in italic

Discussion

APC (adenomatous polyposis coli) was originally identi-
fied as a gene mutated in colorectal cancers associated
with the FAP syndrome, hence the name [1, 25]. Now-
adays, the APC protein is considered a universal tumour
suppressor mostly acting as an antagonist of the Wnt
signaling pathway [26–28]. Moreover, a growing body of
evidence supports the idea that APC performs numerous
functions outside the Wnt pathway: e.g., roles in cell mi-
gration [29], adhesion [30], chromosome segregation
[31], apoptosis [32], and neuronal differentiation [33].
Multifunctionality of the APC protein and the complex
expression pattern of its gene [13, 23] are suggestive of
fairly complicated organisation of the regulatory regions
in the APC gene. So far, however, there is almost no in-
formation about these regions.

In the present study, we for the first time obtained di-
rect evidence of promoter activity of the distal (1B)
(−301; +216; Chr5: 112042901–112043618) and prox-
imal (1A) (−315; +120; chr5: 112073194–112073721) re-
gions of APC, which include start sites for APC’s
alternative transcripts containing exon 1A or 1B. For
these experiments, we cloned these regions into the lu-
ciferase expression vector pGL4.10. The analysis was
conducted on two human cell lines: the colorectal can-
cer HCT-116 cells and erythromyeloblastoid leukaemia
K562 cells: in both cases, activity of promoter 1B was
substantially (approximately sixfold-eightfold) higher
than that of promoter 1A. This result is consistent with
the in vivo data showing that the levels of expression
from promoter 1B are 15- to 250-fold higher as com-
pared with transcripts generated from promoter 1A in
healthy human tissues (gastric and colorectal mucosa,
blood, brain, and small intestine) [13, 23]. In our exper-
iments, the differences in the level of transcription driven
by promoters 1B and 1A were found to be more modest;
this result may have something to do with insufficient size
of the regions inserted into the plasmids and/or differ-
ences in the set of regulatory proteins between tissues of a
live individual and cultured cells. Be that as it may, our
results also clearly show greater activity of promoter 1B.

Next, we studied eleven randomly selected SNPs of
promoter 1A and four from promoter 1B by the EMSA.
Nuclear extracts were prepared from four human cell
lines (HepG2, HeLaS3, HCT-116, and K562). These cell
lines originate from different tissues; this situation expanded the range of nuclear proteins that can bind to specific DNA sites. The results of the EMSA revealed that respectively nine and two of the selected SNPs—in at least one cell line—manifest substantial differences in patterns of binding of nuclear proteins to oligonucleotide probes corresponding to alternative alleles. These differences represented either an increase or decrease in the affinity of some TFs, or even disappearance or appearance of binding sites for TFs. Such alterations in TF binding patterns can strongly influence gene expression [22, 34–36]. Indeed, the luciferase reporter assay suggested that all four analyzed SNPs (which demonstrated differential binding patterns in the EMSA) were functionally active. The most interesting among them was minor allele G (MAF = 0.18) of rs79896135 from promoter 1B; this allele decreased luciferase activity 1.5-fold in the human colorectal cancer HCT-116 cells. Although APC promoter 1B for a long time had been thought to play a minor role in the regulation of this gene, several large deletions that encompass this promoter were found to cause allelic silencing and are known to cause FAP. Our data indicate the possibility of such a negative effect of the substitution C > G (rs79896135) on APC expression in vivo and development of predisposition to FAP, and subsequently colorectal cancer. There are some other interesting substitutions in promoter 1B (rs138386816: C > T and rs115658307: C > T) and in promoter 1A (rs75612255: T > C and rs113017087: T > C), which, on the contrary, increased the luciferase reporter activity.

**Fig. 4** Analysis of activity of reporter constructs. The luciferase activity was measured by the dual-luciferase reporter assay kit (Promega, USA). Firefly luciferase activity was normalized to Renilla luciferase activity. The bars indicated the mean ± SE of the luciferase activity (N = 3–7). **a** Cell line HCT-116. Significant differences * p < 0.05 was assessed by Student’s t test, compared to promoter 1B (Student’s t-test). **b** Cell line K562. Significant differences *** p < 0.001 was assessed by Student’s t test, compared to promoter 1B. Significant differences # p < 0.05 was assessed by Student’s t test, compared to promoter 1A
These findings are suggestive of a possible oncoprotective effect of these substitutions.

Conclusion

Overall, our functional analysis uncovered new possible mechanisms of resistance/susceptibility to oncopathologies with involvement of APC because we demonstrated the effect of a number of rare SNPs located in the alternative promoters of this gene both on nuclear protein binding and promoter activity.

Additional file

Additional file 1: The large clusters of ChiP-Seq peaks is in two distinct regions of APC gene (promoter 1A and promoter 1B). (PNG 44 kb)

Declarations

This article has been published as part of BMC Genetics Vol 17 Suppl 3, 2016: Selected articles from BGRIS58-2016: genetics. The full contents of the supplement are available online at https://bmcgenet.biomedcentral.com/articles/supplements/volume-17-supplement-3.

Funding

The study was funded by the Russian Foundation for Basic Research (grant 15-04-05780) and the Budget Project 0324-2015-0003. The article-processing fee was funded by Russian Foundation for Basic Research (grant 15-04-05780).

Availability of data and materials

All data are presented in the article and in the Additional file 1.

Authors’ contributions

Conceived and designed the experiments: MYM, LOB, EVA, NPB, TIM. Performed the experiments: MYM, EVK, VVR, NPB. Analyzed the data: MYM, LOB, EVA, TIM. Contributed reagents/materials/analysis tools: MYM, EVK, VVR, NPB. Performed the experiments: MYM, EVK, VVR, NPB. Analyzed the data: MYM, LOB, VVR, NPB. Wrote the paper: MYM, TIM. All authors read and approved the final manuscript.

Competing interests

The author declares that he has no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

1Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Lavrentieva avenue 10, Novosibirsk 630090, Russian Federation.
2Novosibirsk State University, Pirogova street 2, Novosibirsk 630090, Russian Federation.

Published: 22 December 2016

References

1. Kintzer KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedges P, McKeehnke D et al. Identification of FAP locus genes from Chromosome 5q21. Science. 1991;253:661–5.
2. Sendra T, Izuka-Kogo A, Onouchi T and Shimomura A. Med Mol Morphol. 2007;40:88–91.
3. Huang D, Du X. Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol. 2008;14(12):1823–7.
4. Yamula R, Kane EG, Moody AE, Politi KA, Lock NE, Foley AV, Roberts DM. Testing models of the APC tumor suppressor/β-catenin interaction rephrases our view of the destruction complex in Wnt signaling. Genetics. 2014(197)(4):1285–302.
5. Galatsatos P, Foulkes D. Familial adenomatous polyposis. Am J Gastroenterol. 2001;96:385–98.
6. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 1995(2):425–34.
7. Niewenhuizen MH, Vassen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007;62(1):153–61.
8. Farlan D, Sahnhane N, Benacondi B, Frattini M, Tiliert MG, Molinari F, Marando A, Zhang L, Vanoli A, Carnesì S, et al. APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. Virchows Arch. 2014;464(5):552–64.
9. Hamilton SR, Liu B, Panons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B, et al. The molecular basis of Turcot’s syndrome. N Engl J Med. 1995;332(13):839–47.
10. Bottarelli L, Azzone C, Pizzio S, D’Adda T, Silini EM, Bordi C, Rindi G. Adenomatous polyposis coli gene involvement in ileal enterochromaffin cell neuroendocrine neoplasms. Hum Pathol. 2013;44(12):2736–42.
11. Fang DC, Luo YH, Yang SM, Li XA, Ling XL, Fang L. Mutation analysis of APC gene in gastric cancer with microsatellite instability. World J Gastroenterol. 2002;8(5):787–91.
12. Lambertz S, Balhausen WG. Identification of an alternative 5’ untranslated region of the adenomatous polyposis coli gene. Hum Genet. 1993;90(6):650–2.
13. Charimes GS, Ramyar L, Mitri A, Berk T, Cheng J, Jang J, Bocangel P, Chodiker B, Greenberg C, Spriggs E, Bapat B. A large novel deletion in the APC promoter region causes gene silencing and leads to classical familial adenomatous polyposis in a Manitoba Mennonite kindred. Hum Genet. 2008;123(5):535–41.
14. Rohlin A, Engwall Y, Fritzell K, Gronasson K, Bergsten A, Einbeigi Z, Nilbert M, Karlsson P, Bjork J, Nordling M. Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis. Oncogene. 2011;30:4977–89.
15. Lin Y, Lin S, Baxter MD, Lin L, Kennedy SM, Zhang Z, Goodfellow PJ, Chapman WC, Davidson MO. Novel APC promoter and exon 1B deletion and allelic silencing in three mutation-negative classic familial adenomatous polyposis genomes. Genome Med. 2015;7(11):42.
16. Hiltunen MO, Ahonen J, Koistinaho J, Myöhänen S, Pääkkönen M, Marin S, Kosma VM, Jänne J. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer. 1997;70(6):644–48.
17. Segditsas S, Sieber OM, Rowan A, Setten F, Neale K, Phillips RK, Ward R, Esteller M, Tomlinson JP. Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp Mol Pathol. 2008;85(3):201–6.
18. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. The Human Gene Mutation Database. 2008 update. Genome Med. 2009;1(11):13.
19. Cooper DN, Chen J, Ball EV, Howells K, Mort M, Phillips AD, Chudanova N, Krawczak M, Lehrer-Sawatzki H, Stenson PD. Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. Hum Mutat. 2010;31:631–55.
20. Zhao Y, Clark WT, Mort M, Cooper DN, Radiovich P, Moorey SD. Prediction of functional regulatory SNPs in monogenic and complex disease. Hum Mutat. 2011;32:1183–90.
21. Bryzgalov LO, Antontseva EV, Matveeva MY, Shilov AG, Kashina EV, Mordvinov VA, Merkulova TL. Detection of regulatory SNPs in human genome using ChiP-seq ENCODE data. PLoS One. 2013;8(10):e78833.
22. Antontseva EV, Matveeva MY, Bondar NP, Kashina EV, Leibeirer E, Bryzgalov LO, Geras P, Ponomareva AA, Chernyntseva NV, Orlov YL, Merkulova TL. Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene. J Biosci. 2011;36:873–83.
23. Hosoya K, Yamashita S, Ando T, Nakajima T, Itoh F, Ushijima T. Adenomatous polyposis coli 1A is likely to be methylated as a passenger in human gastric carcinogenesis. Cancer Lett. 2009;285:182–9.
24. http://www.ncbi.nlm.nih.gov/snp/. (Human Genome Build 37).
25. Groden J, Thilveris A, Samowitz W, Carlson M, Albertsen H, Joslyn G, Stevens J, Spino L, Robertson M, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66(3):589–600.
26. Gupta A, Verma A, Mishra AK, Wadhwa G, Sharma SK, Jain CK, Kaplan K, Burds AA, Swedlow JR, et al. A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol. 2004;6:101–11.
27. Lesko AC, Goss KH, Prosperi JR. Exploiting APC function as a novel cancer therapy. Curr Drug Targets. 2014;15(11):90–102.
28. Xu JH, Hu SL, Shen GD, Shen G. Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy. Cancer Cell Int. 2016;16:13.

29. Watanabe T, Wang S, Noritake J, Sato K, Fukata M, Takefuji M, Nakagawa M, Izumi N, Akiyama T, Kabauchi K. Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell polarization and migration. Dev Cell. 2004;7(6):871–83.

30. Bienz M, Hamada F. Adenomatous Polyposis Coli proteins and cell adhesion. Curr Opin Cell Biol. 2004;16:528–35.

31. Kaplan KB, Burds AA, Swedlow JR, Beier SS, Sorger PK, Naethke IS. A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol. 2001;3(4):29–32.

32. Venesio T, Balsamo A, Scordamaglia A, Bertolaso M, Arrigoni A, Sprujevnik T, Rossini FP, Risio M. Germline APC mutation on the beta-catenin binding site is associated with a decreased apoptotic level in colorectal adenomas. Mod Pathol. 2003;16(1):57–65.

33. Temburni MK, Rosenberg M, Pathak N, McConnell R, Jacob MH. Neuronal nicotinic synapse assembly requires the Adenomatous Polyposis Coli tumor suppressor protein. J Neurosci. 2004;24:6776–84.

34. Ponomarenko JV, Orlov NV, Merkulova TI, Gorshkova EV, Fokin ON, Vasiliev GV, Frolov AS, Ponomarenko MP. rSNP_Guide: an integrated database-tools system for studying SNPs and site-directed mutations in transcription factor binding sites. Hum Mutat. 2002;20:239–48.

35. Van den Boogaard M, Wong LY, TESSADORI F, Bakker ML, Dreizehnter LK, Wakker V, Bezzina CR, Hoep PA, Bakkers J, Barrett P, Christoffels VM. Genetic variation in T-box binding element functionally affects SCNSA/SCN10A enhancer. J Clin Invest. 2012;122:2519–30.

36. Kohanbash G, Ishikawa E, Fujita M, Ikeura M, McKaveney K, Zhu J, Sakaki M, Sarkar SN, Okada H. Differential activity of interferon-α promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma. Oncoimmunology. 2012;1(4):487–92.